Kyverna Therapeutics (KYTX) Cash & Current Investments (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Cash & Current Investments data on file, last reported at $233.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 4.0% year-over-year to $233.0 million; the trailing twelve-month figure through Mar 2026 stood at $233.0 million (down 4.0% YoY), and the FY2025 full-year result was $279.3 million, down 2.35% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $233.0 million, down from $279.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $369.8 million in Q1 2024 and bottomed at $23.0 million in Q3 2023.
• The 4-year median for Cash & Current Investments is $233.0 million (2026), against an average of $202.6 million.
• The widest annual swing landed in 2024, when Cash & Current Investments soared 1300.21%; it then sank 46.78% in 2025.
• A 4-year view of Cash & Current Investments shows it stood at $57.5 million in 2023, then soared by 396.98% to $286.0 million in 2024, then retreated by 2.35% to $279.3 million in 2025, then dropped by 16.58% to $233.0 million in 2026.
• The last three Cash & Current Investments figures came in at $233.0 million (Q1 2026), $279.3 million (Q4 2025), and $171.2 million (Q3 2025), per Business Quant data.

Peer Comparison